Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY (MRK)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Merck and : Animal Health Extends Commitment to Fighting Rabies in the World's Most At Risk Regions

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/03/2017 | 01:45pm CET

Release date- 02102017 - MADISON, N.J. - Today marks the midway milestone for World Rabies Day, when the Global Alliance for Rabies Control, together with health organizations from around the world, set a goal of eliminating human rabies transmitted by dogs by 2030.

Merck Animal Health (known as MSD Animal Health outside the United States and Canada) is pleased to announce our continued support in the fight against rabies through the donation of NOBIVACRabies vaccine and other resources to the Afya Serengeti Project and Mission Rabies, organizations working to eliminate this disease in the world's most at-risk regions.

Rabies, a neglected disease of vulnerable populations, is nearly 100 percent fatal but also nearly 100 percent preventable through canine vaccination. Africa and India still bear the highest burden of total annual rabies deaths.i Countries with the highest fatalities from rabies are India, Democratic Republic of the Congo, Ethiopia, China and Myanmar.ii

'Each year, an estimated 60,000 people die from rabies, with 40 percent of those deaths occurring in children under the age of fifteen,' said Ingrid Deuzeman, global marketing director, Merck Animal Health. 'We are resolved to continue our collaboration with the Afya Serengeti Project, which we've been committed to for more than 15 years, and with Mission Rabies, in support of the global health community goal to eliminate rabies.'

Progress in the Fight Against Rabies

In more than 20 participating countries, when pet owners and veterinarians choose NOBIVAC vaccines, it allows Merck Animal Health to donate rabies vaccine to Mission Rabies and the Afya Serengeti Project.

'Mission Rabies launched at the end of 2013 and to date we've delivered the NOBIVAC Rabies vaccine to 700,000 street dogs in some of the world's worst rabies hotspots. Our flagship projects are delivering amazing results with no human rabies cases having been reported in the Indian city of Ranchi, the State of Goa or the city of Blantyre in Malawi so far this year. It's incredible considering just a few years ago, a hospital in Blantyre (the Queen Elizabeth Central Hospital) was reporting the highest incidence of child rabies deaths from any single institution in the whole of Africa,' said Luke Gamble, founder, Mission Rabies. 'We are all driven to power Mission Rabies forward and without the support of Merck Animal Health NOBIVAC Rabies vaccine, we couldn't do what we do. The vaccine is saving lives amongst some of the poorest and most vulnerable people in the world and it's a privilege to be a part of this project with everyone.'

'The human toll of rabies is needless and tragic. However, over the past 20 years, we have shown that vaccination programs can reach enough dogs to eliminate rabies anywhere in the world,' said Professor Sarah Cleaveland, founder, Afya Serengeti Project. 'With continued support from Merck Animal Health and other collaborators, I believe we have the vaccine and the tools to achieve zero human deaths from dog rabies by 2030.'

Eliminating Rabies in India and Africa

Since 2013, Mission Rabies has set a goal to vaccinate dogs across rabies hotspots in India, where over a third of all human rabies deaths occur.iii Based on the program's success in India, Mission Rabies has expanded its offering to Africa.

Mission Rabies does more than just vaccinate hundreds of thousands of dogs against rabies each year. They go to schools and educate children in these communities, informing them of the seriousness of the disease. Children are the most affected by rabies because they play with dogs and don't understand how deadly rabies can be.

Using a fast-paced team of veterinarians and volunteers, Mission Rabies has so far vaccinated more than 505,000 dogs, trained 80 veterinarians, and educated more than 1,200,000 children about the risk of rabies.

Saving Lives in the Serengeti

The Afya Serengeti Project has prevented thousands of deaths in the Serengeti through the widespread vaccination of domestic dogs. Since the start of the program, the incidence of human rabies, rabies in dogs and rabid dog bites has dropped to an all-time low.iv Each year, over 600 dog rabies cases have been prevented and 23 human lives saved. The effective control of rabies through dog vaccination has also had benefits for wildlife, including endangered African wild dogs, which have become re-established in the Serengeti National Park for the first time since the population disappeared as a result of rabies outbreaks in the early 1990s. Understanding the importance of providing vaccinations to other at-risk areas, the Afya Project has extended to Kenya, Bangalore and the Pune region of India.

About Merck Animal Health

For more than a century, Merck, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global animal health business unit of Merck. Through its commitment to the Science of Healthier Animals, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com or connect with us on LinkedIn, Facebook and Twitter at @MerckAH.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the 'company') includes 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's 2016 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).

Contact:

Tel: 267-305-3558

(c) 2017 Electronic News Publishing -, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK AND COMPANY
12:31p MERCK AND : LYNPARZA® (olaparib) Receives Approval in Japan for the Treatment of..
09:17a MERCK AND : chalks up another win for Keytruda in lung cancer
01/18 MERCK AND : shares continue to rise after successful lung cancer trial
01/18 MERCK AND : The Consumer Health of Merck Walks the Talk with its WE100 Movement
01/17 MERCK AND : KEYTRUDA Significantly Improved Overall Survival and Progression-Fre..
01/17 MERCK AND : Keytruda aces another lung cancer study
01/17 MERCK AND COMPANY : Today’s Research Reports on Stocks to Watch: Bristol-Myers S..
01/17 MERCK AND : Mercks Keytruda combo wows again, acing PhIII overall survival goal ..
01/17 MERCK & CO. INC. : (MRK) Is Up Sharply On Phase 3 Study Results
01/17 Keytruda meets OS, PFS endpoints in first-line NSCLC
More news
News from SeekingAlpha
01/18 Big Biopharma in the red in early trade
01/18 3 THINGS IN BIOTECH YOU SHOULD LEARN : January 17, 2018
01/17 NOVO NORDISK : Don't Spoil The Ablynx Acquisition
01/17 YOUR DAILY PHARMA SCOOP : Eiger Selloff, Novartis' Cosentyx, RXi Outlines Busine..
01/17 U.S. BIOTECH/PHARMA SECTOR DAILY OBS : January 16, 2018
Financials ($)
Sales 2017 40 228 M
EBIT 2017 13 722 M
Net income 2017 5 361 M
Debt 2017 13 208 M
Yield 2017 3,09%
P/E ratio 2017 29,95
P/E ratio 2018 19,67
EV / Sales 2017 4,47x
EV / Sales 2018 4,35x
Capitalization 167 B
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 66,9 $
Spread / Average Target 9,4%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Clark Golestani Chief Information Officer & Executive VP
Roy D. Baynes Chief Medical Officer
Thomas Henry Glocer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY10.24%166 723
JOHNSON & JOHNSON5.11%394 542
NOVARTIS1.02%227 089
PFIZER1.05%218 162
ROCHE HOLDING LTD.-5.33%211 361
AMGEN6.69%134 685